177 related articles for article (PubMed ID: 19319120)
1. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis.
Mu J; Jeyanathan M; Small CL; Zhang X; Roediger E; Feng X; Chong D; Gauldie J; Xing Z
Mol Ther; 2009 Jun; 17(6):1093-100. PubMed ID: 19319120
[TBL] [Abstract][Full Text] [Related]
2. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.
Santosuosso M; McCormick S; Zhang X; Zganiacz A; Xing Z
Infect Immun; 2006 Aug; 74(8):4634-43. PubMed ID: 16861651
[TBL] [Abstract][Full Text] [Related]
3. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.
Santosuosso M; Zhang X; McCormick S; Wang J; Hitt M; Xing Z
J Immunol; 2005 Jun; 174(12):7986-94. PubMed ID: 15944305
[TBL] [Abstract][Full Text] [Related]
5. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.
Xing Z; McFarland CT; Sallenave JM; Izzo A; Wang J; McMurray DN
PLoS One; 2009 Jun; 4(6):e5856. PubMed ID: 19516906
[TBL] [Abstract][Full Text] [Related]
6. Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate.
Shen CF; Jacob D; Zhu T; Bernier A; Shao Z; Yu X; Patel M; Lanthier S; Kamen A
Vaccine; 2016 Jun; 34(29):3381-7. PubMed ID: 27154390
[TBL] [Abstract][Full Text] [Related]
7. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
[TBL] [Abstract][Full Text] [Related]
8. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization.
Xing Z; Lichty BD
Tuberculosis (Edinb); 2006; 86(3-4):211-7. PubMed ID: 16504584
[TBL] [Abstract][Full Text] [Related]
9. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.
Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L
Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321
[TBL] [Abstract][Full Text] [Related]
10. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
[TBL] [Abstract][Full Text] [Related]
11. Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.
Pérez de Val B; Villarreal-Ramos B; Nofrarías M; López-Soria S; Romera N; Singh M; Abad FX; Xing Z; Vordermeier HM; Domingo M
Clin Vaccine Immunol; 2012 Sep; 19(9):1339-47. PubMed ID: 22761299
[TBL] [Abstract][Full Text] [Related]
12. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization.
Santosuosso M; McCormick S; Roediger E; Zhang X; Zganiacz A; Lichty BD; Xing Z
J Immunol; 2007 Feb; 178(4):2387-95. PubMed ID: 17277145
[TBL] [Abstract][Full Text] [Related]
13.
Jia Q; Masleša-Galić S; Nava S; Horwitz MA
mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
[TBL] [Abstract][Full Text] [Related]
14. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.
Radosevic K; Wieland CW; Rodriguez A; Weverling GJ; Mintardjo R; Gillissen G; Vogels R; Skeiky YA; Hone DM; Sadoff JC; van der Poll T; Havenga M; Goudsmit J
Infect Immun; 2007 Aug; 75(8):4105-15. PubMed ID: 17526747
[TBL] [Abstract][Full Text] [Related]
15. Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine.
Roediger EK; Kugathasan K; Zhang X; Lichty BD; Xing Z
Mol Ther; 2008 Jun; 16(6):1161-9. PubMed ID: 18388911
[TBL] [Abstract][Full Text] [Related]
16. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
[TBL] [Abstract][Full Text] [Related]
17. Role of B Cells in Mucosal Vaccine-Induced Protective CD8+ T Cell Immunity against Pulmonary Tuberculosis.
Khera AK; Afkhami S; Lai R; Jeyanathan M; Zganiacz A; Mandur T; Hammill J; Damjanovic D; Xing Z
J Immunol; 2015 Sep; 195(6):2900-7. PubMed ID: 26268652
[TBL] [Abstract][Full Text] [Related]
18. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
[TBL] [Abstract][Full Text] [Related]
19. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.
Hoft DF; Blazevic A; Stanley J; Landry B; Sizemore D; Kpamegan E; Gearhart J; Scott A; Kik S; Pau MG; Goudsmit J; McClain JB; Sadoff J
Vaccine; 2012 Mar; 30(12):2098-108. PubMed ID: 22296955
[TBL] [Abstract][Full Text] [Related]
20. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.
Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z
Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
